Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Public ClinicalTrials.gov record NCT04210115. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
Study identification
- NCT ID
- NCT04210115
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 703 participants
Conditions and interventions
Conditions
Interventions
- 5-FU Drug
- cisplatin Drug
- leucovorin Drug
- levoleucovorin Drug
- oxaliplatin Drug
- pembrolizumab Biological
- placebo Drug
- radiotherapy Radiation
Drug · Biological · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2020
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
- Last update posted
- Nov 14, 2024
2020 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 18
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691) | Long Beach | California | 90806 | — |
| Columbus Regional Research Institute ( Site 0047) | Columbus | Georgia | 31904 | — |
| University of Kansas Cancer Center ( Site 0023) | Westwood | Kansas | 66205 | — |
| Cancer Center of Kansas ( Site 0058) | Wichita | Kansas | 67214 | — |
| University Medical Center ( Site 0035) | New Orleans | Louisiana | 70112 | — |
| Greater Baltimore Medical Center ( Site 0031) | Baltimore | Maryland | 21204 | — |
| Dana Farber Cancer Center ( Site 0034) | Boston | Massachusetts | 02215 | — |
| Henry Ford Hospital ( Site 0685) | Detroit | Michigan | 48202 | — |
| University of Missouri ( Site 0688) | Columbia | Missouri | 65212 | — |
| Renown Regional Medical Center ( Site 0706) | Reno | Nevada | 89502 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0695) | New Brunswick | New Jersey | 08903 | — |
| Weill Cornell Medical College ( Site 0053) | New York | New York | 10065 | — |
| Stephenson Cancer Center ( Site 0044) | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060) | Portland | Oregon | 97239 | — |
| Allegheny Health Network ( Site 0042) | Pittsburgh | Pennsylvania | 15212 | — |
| Thompson Cancer Survival Center ( Site 0696) | Knoxville | Tennessee | 37916 | — |
| Utah Cancer Specialists ( Site 0697) | Salt Lake City | Utah | 84106 | — |
| Cancer Care Northwest - Spokane Valley ( Site 0036) | Spokane Valley | Washington | 99216 | — |
| University of Wisconsin Hospital and Clinics ( Site 0033) | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04210115, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2024 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04210115 live on ClinicalTrials.gov.